Abbott has launched two new haematology instruments, Sekisui CP3000 coagulation system and Alinity hq analyser, to aid high-volume laboratories in addressing productivity needs.
Designed to test bleeding and clotting function, the Sekisui CP3000 coagulation system is a fully automated analyser that requires small sample volumes and features broad assay menu with rapid result turnaround time.
The system allows automated, standardised sample management and identifies unsuitable samples at the beginning of the test.
It is compatible with the firm’s informatics solutions suite that aid in enhancing the efficiency of high test volume laboratories and also with Accelerator a3600 automation track developed to offer additional flexibility to the laboratories.
The Sekisui CP3000 coagulation system is available in Europe, the Middle East and Asia-Pacific.
Abbott exclusively distributes the system in the US and countries that accept CE-Mark and holds non-exclusive distribution rights in China, Hong Kong, Japan and Macau.
The Alinity hq analyser automates the performance of diagnostic haematologic tests that analyse blood composition for various factors such as the identification and quantification of various blood cell types.
Abbott haematology business divisional vice-president and general manager Luis de Luzuriaga said: "The Alinity hq launch is a key milestone for Abbott’s haematology business unit.
"With the Alinity family of harmonised systems, Abbott aims to simplify diagnostics testing across laboratory disciplines and help our customers improve patient outcomes."
The analyser is a part of the firm’s Alinity portfolio and is said to report on 29 different parameters within minutes. It combines advanced optical technology with algorithms to handle both normal and pathological samples.